Neutrophil-lymphocyte ratio in the management and prediction of outcomes in renal cell carcinoma
Neutrophil-lymphocyte ratio in the management and prediction of outcomes in renal cell carcinoma作者机构：Internal MedicineFlinders Private Hospital Geriatric Training Research and Aged Care Centrethe University of Adelaide
出 版 物：《World Journal of Clinical Urology》 (世界临床泌尿杂志)
年 卷 期：2018年第7卷第1期
页 面：1-6页
学科分类：10[医学]
主 题：Neutrophil-lymphocyte ratio Prognosis Renal cell carcinoma Survival
摘 要：Renal cell carcinoma(RCC) is one of the ten most common *** prognosis of RCC is poor when the disease is in advanced stages,with five-year survival of less than 10%.However current assessment approaches are limited in their ability to prognosticate and guide therapeutic ***-mediated inflammatory response is increasingly being recognised to have an important role in carcinogenesis of *** inflammatory markers have been found to identify patients with RCC at high risk of recurrence and predict ***-lymphocyte ratio(NLR) is a simple and inexpensive inflammatory marker that has been shown to be of value in the assessment of patients with *** elevated pretreatment NLR has been found to be associated with reduced overall survival,recurrence-free survival and progress-free survival and risk of recurrence in localized *** addition,lower pretreatment NLR has been demonstrated to be associated with better clinical response to systemic therapy including vascular endothelial growth factor inhibitors,among patients with metastatic ***,NLR has not been found to differentiate whether small renal masses of less than 40 mm are benign or *** research is needed to determine the cut-offs for NLR to predict different clinical outcomes and how post-treatment NLR can be *** addition,more work is also needed to evaluate combining NLR with other biomarkers in a model to predict patients clinical outcome or response to treatment for RCC.
维普期刊数据库